|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Montreal-based company said it had a loss of 71 cents. The drug developer posted revenue of $304,000 in the period. For the year, the company reported that its loss narrowed to ...
Aeterna Zentaris Inc. today announced that Jose M. Garcia, M.D., Ph.D., an Associate Professor of Medicine at the Puget Sound Veterans Administration Hospital and the University of Washington, will present an abstract entitled “Validation of Macimorelin as a Diagnostic Test for Adult Growth Hormone Deficiency : A Phase 3 Study in Comparison with the Insulin Tolerance Test ” from 1:00 pm through 3:00 ...
LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected ...
Aeterna Zentaris Inc. today announced that a poster entitled, “A phase II trial of zoptarelin doxorubicin in castration-and taxane-resistant prostate cancer”, will be presented during the 2017 Genitourinary Cancers Symposium’s “Translating Research to Value-based and Patient-centric Care” by lead investigator, and co-author of the presentation, Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer ...
Aeterna Zentaris Inc. today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ for the evaluation of growth hormone deficiency in adults , using the insulin tolerance test as a comparator, it concluded that Macrilen™ demonstrated performance supportive of achieving registration with the U.S.
Aeterna Zentaris Inc. , announced today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 9:30 AM EST.
Aeterna Zentaris Inc. today announced that it will be presenting at the 2017 BIO CEO & Investor Conference on Monday, February 13 at 8:00 AM EST in New York City.
By Pablo Erbar In a recent interview with Small Cap Nation, CEO David Dodd, of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), and analyst Jeffrey Kraws, of Crystal Research Associates, came together for a discussion regarding the present and future of the biopharmaceutical drug development company. The finalization of testing and subsequent commercialization of the two Phase […]
Aeterna Zentaris Inc. today announced the occurrence of the 384th death in the pivotal Phase 3 ZoptEC study with Zoptrex™ in women with advanced, recurrent or metastatic endometrial cancer, representing the clinical endpoint of the study.